The diagnostic value of SPECT with Tc 99m HMPAO in alzheimer’s disease: A population-based study

Neurology

Volumn 44, Issue 3, 1994, Pages 454-461

  Claus, J J ^a   van Harskamp, F ^a   Breteler, M M B ^a   Krenning, E P ^a   de Koning, I ^a   van der Cammen, T J M ^a   Hofman, A ^a   Hasan, D ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN BLOOD FLOW; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGRESSION ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; CEREBROVASCULAR CIRCULATION; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; OXIMES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M EXAMETAZIME; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0028280849     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.44.3_part_1.454     Document Type: Article

References (26)

1. Rocca WA, Hofman A, Brayne C, et al. Frequency and distribution of Alzheimer’s disease in Europe: a collaborative study of 1980-1990 prevalence findings. Ann Neurol 1991;30:381-390.
2. Katzman R. Alzheimer’s disease. N Engl J Med 1986;314: 964-973.
3. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939-944.
4. Work Group to Revise DSM III. Dementia arising in the senium and presenium. In: Spitzer RL, et al, eds. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1987:119-123.
5. Storandt M, Hill RD. Very mild senile dementia of the Alzheimer type II. Psychometric test performance. Arch Neurol 1989;46:383-386.
6. Gado M, Hughes CP, Danziger W, Chi D. Aging, dementia, and brain atrophy: a longitudinal computed tomographic study. AJNR 1983;4:699-702.
7. Procter AW, Lowe SL, Palmer AM, et al. Topographical distribution of neurochemical changes in Alzheimer’s disease. J Neurol Sci 1988;84:125-140.
8. Katzman R, Terry R, DeTeresa R, et al. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol 1988;23:138-144.
9. Crystal H, Dickson D, Fuld P, et al. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer’s disease. Neurology 1988;38:1682- 1687.
10. Gemmell HG, Sharp PF, Besson JAO, et al. Differential diagnosis in dementia using the cerebral blood flow agent 99mTc HM-PAO: a SPECT study. J Comput Assist Tomogr 1983;7:580-598.
11. Bums A, Philpot MP, Costa DC, Ell PJ, Levy R. The investigation of Alzheimer’s disease with single photon emission tomography. J Neurol Neurosurg Psychiatry 1989;52:248-253.
12. Montaldi D, Brooks DN, McColl JH, et al. Measurements of regional cerebral blood flow and cognitive performance in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1990; 53:33-38.
13. Battistin L, Pizzolato G, Dam M, et al. Regional cerebral blood flow study with 99mTc-hexamethyl-propylene amine oxime single photon emission tomography in Alzheimer’s and multi-infarct dementia. Eur Neurol 1990;30:296-301.
14. Hurwitz TA, Ammann W, Chu D, Clark C, Holden J, Brown- stone R. Single photon emission computed tomography using "mTc HM-PAO in the routine evaluation of Alzheimer’s disease. Can J Neurol Sci 1991;18:59-62.
15. Habert MO, Spampinato U, Mas JL, et al. A comparative technetium 99m hexamethylpropylene amine oxime SPET study in different types of dementia. Eur J Nucl Med 1991;18:3-11.
16. Perani D, Di Piero V, Vallar G, et al. Technetium-99m HMPAO SPECT study of regional cerebral perfusion in early Alzheimer’s disease. J Nucl Med 1988;29:1507-1514.
17. Holman BL, Johnson KA, Gerada B, Carvalho PA, Satlin A. The scintigraphic appearance of Alzheimer’s disease: a prospective study using technetium-99m HM-PAO SPECT. J Nucl Med 1992;33:181-185.
18. O’Brien JT, Eagger S, Syed GMS, Sahakian BJ, Levy R. A study of regional cerebral blood flow and cognitive performance in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1992;55:1182-1187.
19. Reisberg B, Ferris SH, de Leon MJ, Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-1139.
20. Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state.’ A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
21. Hofman A, Grobbee DE, De Jong PTVM, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991;7:403-422.
22. Breteler MMB, van den Ouweland FA, Grobbee DE. A community-based study of dementia: the Rotterdam Elderly Study. Neuroepidemiology 1992;ll(suppl 1):23-28.
23. Lear JL. Quantitative local cerebral blood flow measurement with technetium-99m HM-PAO: evaluation using multiple radionuclide digital quantitative autoradiography. J Nucl Med 1988;29:1387-1392.
24. Yonekura Y, Nishizawa S, Mukai T, et al. SPECT with 99mTc hexamethyl-propylene amine oxime (HM-PAO) compared with regional cerebral blood flow measured by PET: effect of linearization. J Cereb Blood Flow Metab 1988; 8(11):82-89.
25. Gemmell HG, Evans NTS, Besson JAO, et al. Regional cerebral blood flow imaging: a quantitative comparison of tech- netium-99m HM-PAO SPECT with C1502 PET. J Nucl Med 1990;31:1595-1600.
26. Aquilonius SM, Eckernas SA. A color atlas of the human brain. New York: Raven Press, 1980.